Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
about
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsConnexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis opticaAnti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotypeThe innate immune system in demyelinating diseaseClinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumabAquaporin 4 and neuromyelitis opticaThe Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future PerspectivesAntibodies as Mediators of Brain PathologyB Cells and Autoantibodies in Multiple SclerosisAtypical presentations of neuromyelitis opticaDevelopment, maintenance and disruption of the blood-brain barrierChallenges and opportunities in designing clinical trials for neuromyelitis opticaImmunology of neuromyelitis optica: a T cell-B cell collaborationMolecular pathogenesis of neuromyelitis opticaAquaporin 4: a player in cerebral edema and neuroinflammationAntigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune DiseasesAntibody biomarkers in CNS demyelinating diseases - a long and winding roadPotassium channel KIR4.1 as an immune target in multiple sclerosisNeuromyelitis optica lesions may inform multiple sclerosis heterogeneity debateThe astrocyte in multiple sclerosis revisitedThe spectrum of MOG autoantibody-associated demyelinating diseasesBiomarkers of treatment response in multiple sclerosisAstrocytopathy in Balo's diseaseCurrent concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination.Aquaporin-4 autoantibodies increase vasogenic edema formation and infarct size in a rat stroke modelNeuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria.Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica.Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.Experimental models of neuromyelitis optica.Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis opticaAquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica.Identification of peptide targets in neuromyelitis optica.
P2860
Q21093230-1DAC898F-06AA-4D41-A101-3CED15F2703CQ21132530-3B20F647-5FF3-4DA2-B47E-61A64BF073D1Q21146662-F18446F7-D0DD-4D1E-A6F0-AB93662F7A9FQ24597958-E28ACBA9-16A8-446A-923A-3672572E6FBAQ24598109-CD727F5F-434D-4A85-9CE9-870A9A773E08Q24613666-0C3F07AC-1306-40D8-BA5D-48671D1BFB0BQ26767391-1380F43C-7C96-41A4-A077-9DE1F68492BEQ26780374-50149A6C-1FCD-41E8-B453-9E8F570DF6ECQ26801386-50C4DCFC-D81D-4A2A-B089-9227C66B84EBQ26827156-72C69969-0624-4BED-A58A-A3F550853BE4Q26829668-9887F74E-D51A-4BE6-A907-FC4177566DDCQ26999708-215B0750-E1BD-489E-8A30-820905709CEAQ27016045-B7D4CC28-BDFC-4F7C-8E00-A640FC1F3625Q27021535-A42C5076-CA3E-4B57-B4CA-778C755A940DQ27022405-251DDE64-807C-499E-9ABD-27F22475B869Q28080791-664250F8-AACD-4E35-B64D-AC401543770BQ28262403-CFDC5BAB-F505-4E26-8A51-2C7894A01803Q28270799-8BBF377E-08D4-465F-9E87-ADF1FB4FCF78Q28276365-1CA6B047-80CC-48EE-BE5F-CC83003CE065Q28283441-BDD2280B-1CA3-45BB-B2E3-0ADDF98782CEQ28293355-C4E3A594-F624-4B63-95B8-0245773A527FQ28305094-D45D1C73-09E5-4D88-AC82-4E51A5053A3CQ28308173-0F720771-6B5D-4B6E-9F23-534722C719B2Q30577078-FD006CAE-1685-4ECA-90D4-6F5CB913D165Q30610471-DBA5B900-B32B-4116-9D4E-C570895B9658Q30676331-32479AD4-324C-49BB-8F87-D884D9ED96DEQ30785267-252E5B62-DB35-4BEE-A749-0AAF24E80923Q30833332-DB750296-81E9-4A7D-9755-82916EF26D06Q30842875-AC7B5034-E521-41EE-AC70-984325C89033Q30953714-0193FC7F-ECEC-49A2-A4A3-E019D4F27524Q30975717-2F3EA428-7FF8-4C8F-B379-9CA4649D0216Q33567268-D3BEBAB8-8139-4D6E-BC83-2CCD96AE9E99Q33576962-D250F891-051B-4208-89DA-F9C19F9CB246Q33656297-810B7094-889C-4678-AB53-9043CADB175DQ33769028-BB05EF97-CB6A-4CBF-A35D-EC667C029E07Q33770508-C0D0F593-8CCD-40B9-9E0D-51E45AC443C0Q33785380-492980D3-98A2-4DFC-831E-79C774BC4430Q33802616-5602A287-E6CD-4127-85EC-4AA0A11E96FCQ33892339-EBFF67CA-5584-4475-96A1-413FAEAE84B7Q33914842-84CC54FA-2FA3-4188-BD09-9C42323D7BF4
P2860
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@en
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@nl
type
label
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@en
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@nl
prefLabel
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@en
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
@nl
P2093
P50
P356
P1433
P1476
Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo
@en
P2093
Kazuo Fujihara
Milena Adzemovic
Mitsutoshi Watanabe
Tatsuro Misu
Thomas Berger
Toshiyuki Takahashi
Yasuto Itoyama
P2860
P304
P356
10.1002/ANA.21837
P577
2009-11-01T00:00:00Z